159 related articles for article (PubMed ID: 26352580)
1. New drugs in ovarian cancer.
Fleming GF
Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
[No Abstract] [Full Text] [Related]
2. [No available].
Sabourin G
Perspect Infirm; 2016; 13(2):59. PubMed ID: 27158729
[No Abstract] [Full Text] [Related]
3. Regulatory considerations on endpoints in ovarian cancer drug development.
Balasubramaniam S; Kim GS; McKee AE; Pazdur R
Cancer; 2017 Jul; 123(14):2604-2608. PubMed ID: 28499075
[TBL] [Abstract][Full Text] [Related]
4. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
5. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
6. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
7. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Duan P; Fan L; Gao Q; Silwal BM; Ren M; Shen Y; Qu W
Curr Drug Targets; 2017; 18(10):1171-1178. PubMed ID: 28443505
[TBL] [Abstract][Full Text] [Related]
9. [The Update and the Future of Antiangiogentic Agents].
Togami S; Kobayashi H
Gan To Kagaku Ryoho; 2016 Feb; 43(2):176-81. PubMed ID: 27093727
[No Abstract] [Full Text] [Related]
10. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
[TBL] [Abstract][Full Text] [Related]
11. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
12. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
13. Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
Ferrara N
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059427
[No Abstract] [Full Text] [Related]
14. A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.
Yin X; Wang X; Shen B; Jing Y; Li Q; Cai MC; Gu Z; Yang Q; Zhang Z; Liu J; Li H; Di W; Zhuang G
Sci Rep; 2016 Aug; 6():31079. PubMed ID: 27498762
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.
Markowska A; Sajdak S; Markowska J; Huczyński A
Eur J Med Chem; 2017 Dec; 142():87-94. PubMed ID: 28651817
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
Martin L; Schilder R
J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
19. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
20. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
